Interferon α extends the survival of human myeloma cells through an upregulation of the Mcl-1 anti-apoptotic molecule

被引:44
作者
Puthier, D
Thabard, W
Rapp, MJ
Etrillard, M
Harousseau, JL
Bataille, R
Amiot, M
机构
[1] Inst Biol, INSERM, U463, F-44093 Nantes 01, France
[2] CHU Nantes, Dept Hematol, F-44035 Nantes, France
关键词
multiple myeloma; IFN-alpha; Mcl-1; STAT3; IL-6;
D O I
10.1046/j.1365-2141.2001.02575.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We have recently reported that Mcl-1, an anti-apoptotic member of the Bcl-2 family, is upregulated by interleukin (IL)-6 in human myeloma cells through the janus kinase/signal transducers and activators of transduction (JAK/STAT) pathway. In the current study, we have explored the effects of interferon (IFN)-alpha, a cytokine which has been shown to increase myeloma cell survival. Our results demonstrate that IFN-alpha potently upregulates Mcl-1 on both myeloma cell lines and purified native myeloma cells. Of note, this upregulation is not due to an induction of an IL-6 autocrine loop. Furthermore, we showed that IL-6 and IFN-alpha had no additive effect on Mcl-1 upregulation, suggesting that both cytokines act through a common mechanism. Finally, the analysis of signalling transduction pathways strongly suggests that Mcl-1 upregulation induced by IFN-alpha depends on STAT3 activation. Altogether, our data show that IFN-alpha has an IL-6-like effect on human myeloma cells and suggest that it could be deleterious in some patients.
引用
收藏
页码:358 / 363
页数:6
相关论文
共 27 条
[1]   Reversal of EBV immortalization precedes apoptosis in IL-6-induced human B cell terminal differentiation [J].
Altmeyer, A ;
Simmons, RC ;
Krajewski, S ;
Reed, JC ;
Bornkamm, GW ;
ChenKiang, S .
IMMUNITY, 1997, 7 (05) :667-677
[2]  
Arora T, 1999, J IMMUNOL, V162, P3289
[3]   Multiple myeloma [J].
Bataille, R ;
Harousseau, JL .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (23) :1657-1664
[4]   DEVELOPMENT OF AGGRESSIVE PLASMA-CELL LEUKEMIA UNDER INTERFERON-ALPHA THERAPY [J].
BLADE, J ;
LOPEZGUILLERMO, A ;
TASSIES, D ;
MONTSERRAT, E ;
ROZMAN, C .
BRITISH JOURNAL OF HAEMATOLOGY, 1991, 79 (03) :523-525
[5]   Viewpoint on the impact of interferon in the treatment of multiple myeloma:: benefit for a small proportion of patients? [J].
Bladé, J ;
Esteve, J .
MEDICAL ONCOLOGY, 2000, 17 (02) :77-84
[6]  
BRENNING G, 1986, SCAND J HAEMATOL, V37, P280
[7]   Stat3 as an oncogene [J].
Bromberg, JF ;
Wrzeszczynska, MH ;
Devgan, G ;
Zhao, YX ;
Pestell, RG ;
Albanese, C ;
Darnell, JE .
CELL, 1999, 98 (03) :295-303
[8]   Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells [J].
Catlett-Falcone, R ;
Landowski, TH ;
Oshiro, MM ;
Turkson, J ;
Levitzki, A ;
Savino, R ;
Ciliberto, G ;
Moscinski, L ;
Fernández-Luna, JL ;
Nuñez, G ;
Dalton, WS ;
Jove, R .
IMMUNITY, 1999, 10 (01) :105-115
[9]   PHASE-I-II TRIAL OF INTERFERON-ALPHA-2B BY CONTINUOUS SUBCUTANEOUS INFUSION OVER 28 DAYS [J].
DORR, RT ;
SALMON, SE ;
ROBERTONE, A ;
BONNEM, E .
JOURNAL OF INTERFERON RESEARCH, 1988, 8 (06) :717-725
[10]  
DURIE BGM, 1986, SEMIN ONCOL, V13, P300